v3.26.1
Royalty Revenue Monetization (Tables)
6 Months Ended
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Liability Related to Sale of Future Royalties
The following is a summary of the Company's liability related to sale of future royalties for the six months ended June 30, 2026:
Proceeds from sale of future royalties in March 2026
$250,000 
Issuance costs related to sale of future royalties
(5,563)
Royalty payments to Royalty Pharma
(467)
Interest expense related to sale of future royalties
8,548 
Amortization of issuance costs
$113 
Net Liability related to sale of future royalties as of June 30, 2026
$252,631